Kenneth Pettine, MD, performed the procedure. During the trial, surgeons place a minimally invasive injection of Mesoblast’s allogenic MPCs into the patient’s severely damaged intervertebral discs. The injection is designed to reverse the degenerative process, regrow disc cartilage and sustain normalization of disc pathology, anatomy and function for six months.
The FDA trial will enroll 100 patients with chronic low back pain due to DDD in 15 centers across the United States and Australia to compare six-month outcomes. There will be 60 patients who receive MPC injections and 40 patients who receive control injections.
Related Articles on Stem Cells in Spine Surgery:
5 Things to Know About the Use of Stem Cells in Spine Surgery
Dr. Damon Noto Performs Spine Procedures With Stem Cells
Dr. Stanley Jones Performs Stem Cell Infusion Spine Surgery for Texas Governor
